UCB has announced its consolidated full year 2008 financial results. It was a year of solid operational achievement which accelerated the transformation of the company towards becoming a focused biopharmaceutical company.
“UCB has completed a year of significant execution. We delivered stable revenue and strong underlying profitability, successfully absorbing the anticipated loss from the major patent expiry of Zyrtec in the U.S. in December 2007 and from the loss of exclusivity for Keppra in the U.S. in November 2008. This included the approval of three new molecular entities in the U.S. providing the fuel for future growth”, said Roch Doliveux, Chief Executive Officer, UCB. “With the launch of the SHAPE programme, UCB continued its transformation into a focused, specialist biopharma company concentrated on severe diseases of the central nervous system and immunology, thereby improving its competitiveness and profitability, and sharpening its ability to bring benefits to patients with severe disease.”
For a full report, visit: UCB